ACRP CCRC Exam Prep Questions and Answers
2023/2024 Complete
What are expected or possible consequences of over-estimation of recruitment
potential?
- The trial will overrun its projected timeline
- The recruitment period will be prolonged and more sites may be needed
- The study will not have sufficient data within the required timeframe and will be
stopped because of lack of budget
What should be the first consideration when conducting a clinical trial?
Subject welfare
When is the investigator allowed to deviate from the protocol?
When there is an immediate hazard to a patient.
If the investigator wanted to deviate from the protocol for an immediate hazard to
a patient, according to ICH E6 guidelines who world they need to report the
deviation and rationale to, if appropriate?
- The Sponsor
- IRB/IEC
- Regulatory Authorities
Which conditions should be fulfilled when enrolling a subject into your trial?
- Subject meets all inclusion criteria
- Subject has given written informed consent
You've been delegated to handle the storage and inventory of IP. The study drug
must be stored below 25C/77F. On a summer Monday morning you discover that
the temperature recording machine in the storage room has failed so you doin't
know what the temperature has been over the weekend. You check the current
temperature; it's 24C/75F. What should you do?
- Contact the Sponsor, explain what happened and ask for instructions
- Set up a site staff meeting to conduct a root cause analysis
A protocol amendment was issued for a trial. Your site received IRB approval for
the amendment and wants to implement the increase in PO dose for your trial
subjects as identified in the amendment trial subjects. As delegated consenting
duties you must re-consent trial subjects before being able to administer the
adjusted dose. You decide to only re-consent trial subjects who are still taking
the IP and not from the subjects woh already completed their drug intake period.
Is this allowed according the E6 Guideline for GCP?
No, these subjects are still enrolled in the trial and therefore need to be updated on any
changes to the protocol.
A trial subject informs you she no longer wants to participant in the trial. What
should your course of action be?
You ask if the patient wishes to share the reason why she wants to leave the trial. If not,
you exclude the subject from the trial immediately.
A patient cannot recall the name of the heart condition medication he took a few
years ago. This is important information for deciding whether the patient may be
enrolled in a clinical trial (IC/EC). What's your best course of action?
,You attempt to retrieve the patients medical history by contacting previous caregivers
and you wait for additional information before enrollment.
Who has ultimate trial responsibility for each subject?
The principle investigator.
A trial subject suffers from severe repeat headaches. Should this adverse event
be reported to the IRB?
No
What statements are true concerning an adverse drug reaction?
- All noxious and unintended responses to a medicinal product related to any dose
should be considered as an ADR
- An ADR suggests a relationship to trail medication
- All ADRs must be documented
What Adverse Events (AEs) are Serious Adverse Events (SAEs)?
- Any AE that results in death
- Any AE that results in inpatient hospitalization
- Any AE that is a congenital anomaly
During a study visit a patient tells the investigator that she visited an emergency
room and received intensive treatment for allergic bronchospasm. Since the
patient was in the emergency room for only three hours, the investigator did not
assess the event as serious. Is this a correct assessment?
No, this would be a medically important event and should be considered serious
What data points minimally need to be reported by the site when reporting an
SAE, so that the sponsor can process the event?
Identification of event, product, and trial subject
During a visit with investigator, a subject reported feeling heart palpitations for a
brief period of time during the previous evening. The heart palpitations resolved
without reoccurrence. The investigator considered these symptoms to be
unrelated to study drug. The next day, the subject told a fellow student that he felt
tired and was planning on taking a nap. Later, the subject was found dead. A
preliminary report from the medical examiner indicated the subject died of
pulmonary embolism. What should your next course of action be?
- Record these events in case report form
- Immediately notify sponsor about serious adverse events
When asked by a regulatory body why they received SAE related information on
12/2013 from an incident that occurred in 5/2013, the sponsor explained the
reason being they received the trial related SAE information from the investigator
in 12/2013. Is the sponsor correct in only holding the investigator accountable for
their late reporting?
No, the sponsor should support the conduct QC activities with the sites to help them
ensure timely SAE reporting.
A trial subject in a cardiology trial is admitted to hospital with heart attack. The
investigator considers this event possibly related to the study drug even though
this is not listed in the IB as a potential adverse reaction. What would the
investigator report this event to the sponsor as?
An unexpected, serious adverse event
, A 22y/o male was entered into a clinical study for treatment of schizophrenia The
study drug was administered orally, BID. One week later, the subject visited the
investigator complaining of sever sore throat. The IB lists this as an occurrence
reported by 1% of subjects receiving drug. How should this severe throat be
classified?
- An adverse event
- An adverse drug reaction
In regards to AE and ADR reporting, what statements are true?
- All ADRs are AEs but not all AEs are ADRs
- Worsening in pre-existing medical conditions is an AE
-Preplanned hospitalization is usually not an SAE
What determines the causality of an adverse event?
The investigator
Which term best describes the cyclical process that involves the Plan, Do, Check,
Act activities?
Quality improvement
Which term best describes an independent assessment of completed work to
ensure it will meet applicable quality standards?
Quality assurance
Which term best describes the activities done to ensure quality output?
Quality control
Which term requires structure and a definition of acceptable standards of
performance?
Quality planning
Which is represented in ALCOA-C?
Attributable
What does CAPA stand for?
Corrective and Preventive Action
When not completed correctly, which is a major contributing factor to an
ineffective CAPA plan?
Root cause analysis
What are the cyclical activities performed a part of quality improvement?
Plan, Do, Check, Act
What is sued to determine root causes?
- Fishbone diagram
- Process flow charts
- The 5 Whys
What are fishbone diagrams, process flow charts, and the 5 whys used for
determining?
Root causes
What is the key difference between quality improvement and quality assurance
activities?
Can be performed by persons involved in doing the work.
What are the elements of quality management system?
2023/2024 Complete
What are expected or possible consequences of over-estimation of recruitment
potential?
- The trial will overrun its projected timeline
- The recruitment period will be prolonged and more sites may be needed
- The study will not have sufficient data within the required timeframe and will be
stopped because of lack of budget
What should be the first consideration when conducting a clinical trial?
Subject welfare
When is the investigator allowed to deviate from the protocol?
When there is an immediate hazard to a patient.
If the investigator wanted to deviate from the protocol for an immediate hazard to
a patient, according to ICH E6 guidelines who world they need to report the
deviation and rationale to, if appropriate?
- The Sponsor
- IRB/IEC
- Regulatory Authorities
Which conditions should be fulfilled when enrolling a subject into your trial?
- Subject meets all inclusion criteria
- Subject has given written informed consent
You've been delegated to handle the storage and inventory of IP. The study drug
must be stored below 25C/77F. On a summer Monday morning you discover that
the temperature recording machine in the storage room has failed so you doin't
know what the temperature has been over the weekend. You check the current
temperature; it's 24C/75F. What should you do?
- Contact the Sponsor, explain what happened and ask for instructions
- Set up a site staff meeting to conduct a root cause analysis
A protocol amendment was issued for a trial. Your site received IRB approval for
the amendment and wants to implement the increase in PO dose for your trial
subjects as identified in the amendment trial subjects. As delegated consenting
duties you must re-consent trial subjects before being able to administer the
adjusted dose. You decide to only re-consent trial subjects who are still taking
the IP and not from the subjects woh already completed their drug intake period.
Is this allowed according the E6 Guideline for GCP?
No, these subjects are still enrolled in the trial and therefore need to be updated on any
changes to the protocol.
A trial subject informs you she no longer wants to participant in the trial. What
should your course of action be?
You ask if the patient wishes to share the reason why she wants to leave the trial. If not,
you exclude the subject from the trial immediately.
A patient cannot recall the name of the heart condition medication he took a few
years ago. This is important information for deciding whether the patient may be
enrolled in a clinical trial (IC/EC). What's your best course of action?
,You attempt to retrieve the patients medical history by contacting previous caregivers
and you wait for additional information before enrollment.
Who has ultimate trial responsibility for each subject?
The principle investigator.
A trial subject suffers from severe repeat headaches. Should this adverse event
be reported to the IRB?
No
What statements are true concerning an adverse drug reaction?
- All noxious and unintended responses to a medicinal product related to any dose
should be considered as an ADR
- An ADR suggests a relationship to trail medication
- All ADRs must be documented
What Adverse Events (AEs) are Serious Adverse Events (SAEs)?
- Any AE that results in death
- Any AE that results in inpatient hospitalization
- Any AE that is a congenital anomaly
During a study visit a patient tells the investigator that she visited an emergency
room and received intensive treatment for allergic bronchospasm. Since the
patient was in the emergency room for only three hours, the investigator did not
assess the event as serious. Is this a correct assessment?
No, this would be a medically important event and should be considered serious
What data points minimally need to be reported by the site when reporting an
SAE, so that the sponsor can process the event?
Identification of event, product, and trial subject
During a visit with investigator, a subject reported feeling heart palpitations for a
brief period of time during the previous evening. The heart palpitations resolved
without reoccurrence. The investigator considered these symptoms to be
unrelated to study drug. The next day, the subject told a fellow student that he felt
tired and was planning on taking a nap. Later, the subject was found dead. A
preliminary report from the medical examiner indicated the subject died of
pulmonary embolism. What should your next course of action be?
- Record these events in case report form
- Immediately notify sponsor about serious adverse events
When asked by a regulatory body why they received SAE related information on
12/2013 from an incident that occurred in 5/2013, the sponsor explained the
reason being they received the trial related SAE information from the investigator
in 12/2013. Is the sponsor correct in only holding the investigator accountable for
their late reporting?
No, the sponsor should support the conduct QC activities with the sites to help them
ensure timely SAE reporting.
A trial subject in a cardiology trial is admitted to hospital with heart attack. The
investigator considers this event possibly related to the study drug even though
this is not listed in the IB as a potential adverse reaction. What would the
investigator report this event to the sponsor as?
An unexpected, serious adverse event
, A 22y/o male was entered into a clinical study for treatment of schizophrenia The
study drug was administered orally, BID. One week later, the subject visited the
investigator complaining of sever sore throat. The IB lists this as an occurrence
reported by 1% of subjects receiving drug. How should this severe throat be
classified?
- An adverse event
- An adverse drug reaction
In regards to AE and ADR reporting, what statements are true?
- All ADRs are AEs but not all AEs are ADRs
- Worsening in pre-existing medical conditions is an AE
-Preplanned hospitalization is usually not an SAE
What determines the causality of an adverse event?
The investigator
Which term best describes the cyclical process that involves the Plan, Do, Check,
Act activities?
Quality improvement
Which term best describes an independent assessment of completed work to
ensure it will meet applicable quality standards?
Quality assurance
Which term best describes the activities done to ensure quality output?
Quality control
Which term requires structure and a definition of acceptable standards of
performance?
Quality planning
Which is represented in ALCOA-C?
Attributable
What does CAPA stand for?
Corrective and Preventive Action
When not completed correctly, which is a major contributing factor to an
ineffective CAPA plan?
Root cause analysis
What are the cyclical activities performed a part of quality improvement?
Plan, Do, Check, Act
What is sued to determine root causes?
- Fishbone diagram
- Process flow charts
- The 5 Whys
What are fishbone diagrams, process flow charts, and the 5 whys used for
determining?
Root causes
What is the key difference between quality improvement and quality assurance
activities?
Can be performed by persons involved in doing the work.
What are the elements of quality management system?
